Dr. Shane R. Stecklein, M.D., PH.D.
Radiation Oncology (Radiation Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 222
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Radiation Oncology Physician primary
FL license ME176753 · KS license 04-41941 · MO license 2019008077
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- Orlando Health Orlando, FL
- University of Kansas Health System - St Francis Campus Topeka, KS
Medical groups
- Orlando Health Medical Group Inc (2,287 clinicians)
- Kansas University Physicians Inc (1,849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 222
- Services billed
- 1,196
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | 239 | 98 |
| Design and construction of complex radiation treatment device | 173 | 45 |
| Calculation of radiation therapy dose | 173 | 43 |
| Radiation treatment management, 5 treatment sessions | 81 | 44 |
| Established patient office or other outpatient visit, 30-39 minutes | 51 | 47 |
| Complex radiation therapy planning | 44 | 40 |
| New patient office or other outpatient visit, 60-74 minutes | 43 | 43 |
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 28 |
| 3d radiation therapy planning | 30 | 28 |
| Obtaining data needed to develop the optimal radiation treatment, 3 or more treatment areas or any number of treatment areas where special treatment is involved | 29 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $61.98 in total to this clinician.
| Merck Sharp & Dohme LLC | $31.39 |
|---|---|
| Stryker Corporation | $30.59 |
| Food and Beverage | $61.98 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $43,427 in research payments for these studies, mostly to the institutions running them.
- A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in combination with ribocilcib and fulvestrant in subjects participants withER-positive, HER2- negative and GRPR-positive breast cancer, ex…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.